Dr Reddy's On Digitization Amid COVID-19, 'Lights-Out' Manufacturing
Remote Inspections Were 'Good Learning'
Executive Summary
Dr Reddy’s global head of quality outlines how the company leveraged digitization to keep plants running at full throttle amid the pandemic and went on to operationalize a site for remdesivir designed as a "lights out" facility. Certain facilities at the Indian firm have also undergone remote inspections by major regulatory agencies.
You may also be interested in...
Respiratory Plus: Cipla Shapes Future In New Age Platforms, Devices, Diagnostics
The next chapter of Cipla’s innovation journey goes beyond its core respiratory thrust to include new platforms spanning areas such as peptides, where it has seen its first major approval in the US and has multiple programs lined up. Devices and diagnostics are among the other avenues being explored as the Indian company seeks to bring more patients into the “funnel”.
Re-Configuring Pharma Operations Amid Pandemic Strains
Senior McKinsey executive shares insights on the potential contours of pharma’s 'reimagined' operations against the backdrop of COVID-19 and striking a balance between supply chain security and the cost component. A dramatic near-term shift to a “completely onshore model” in markets like the US would not realistically be possible, he indicated.
US FDA Mulls Possibility Of Preannouncing Post-COVID Domestic Surveillance Inspections
Criticized for giving foreign sites advance notice of inspections, agency is considering giving such notice to domestic sites too even after surprise inspections become possible.